282 related articles for article (PubMed ID: 19891585)
1. High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis.
Miyakawa K; Tarao K; Ohshige K; Morinaga S; Ohkawa S; Okamoto N; Shibuya A; Adachi S; Miura Y; Fujiyama S; Miyase S; Tomita K
Scand J Gastroenterol; 2009; 44(11):1340-8. PubMed ID: 19891585
[TBL] [Abstract][Full Text] [Related]
2. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
[TBL] [Abstract][Full Text] [Related]
3. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
4. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
5. Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of child stage A.
Tarao K; Rino Y; Ohkawa S; Endo O; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Nagaoka T; Okamoto N; Tanaka K; Tarao N
Intervirology; 2004; 47(2):65-71. PubMed ID: 15192269
[TBL] [Abstract][Full Text] [Related]
6. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
[TBL] [Abstract][Full Text] [Related]
7. Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma.
Mahmood S; Niiyama G; Kamei A; Izumi A; Nakata K; Ikeda H; Suehiro M; Kawanaka M; Togawa K; Yamada G
Liver Int; 2005 Apr; 25(2):220-5. PubMed ID: 15780042
[TBL] [Abstract][Full Text] [Related]
8. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis.
Aizawa Y; Shibamoto Y; Takagi I; Zeniya M; Toda G
Cancer; 2000 Jul; 89(1):53-9. PubMed ID: 10897000
[TBL] [Abstract][Full Text] [Related]
9. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.
Pekow JR; Bhan AK; Zheng H; Chung RT
Cancer; 2007 Jun; 109(12):2490-6. PubMed ID: 17487861
[TBL] [Abstract][Full Text] [Related]
10. Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: comparison in patients with hepatitis B virus- and hepatitis C virus-associated cirrhosis.
Sato A; Kato Y; Nakata K; Nakao K; Daikoku M; Ishii N; Matsumoto T; Iseki K; Mazume H; Nagataki S
J Gastroenterol Hepatol; 1996 Oct; 11(10):944-8. PubMed ID: 8912132
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
Rodríguez-Díaz JL; Rosas-Camargo V; Vega-Vega O; Morales-Espinosa D; Mendez-Reguera A; Martínez-Tlahuel JL; Gamboa-Domínguez A; Arrieta O
Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):197-203. PubMed ID: 17359907
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.
Chen DS
Princess Takamatsu Symp; 1995; 25():27-32. PubMed ID: 8875606
[TBL] [Abstract][Full Text] [Related]
13. Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels.
Kobayashi M; Suzuki F; Akuta N; Suzuki Y; Sezaki H; Yatsuji H; Kawamura Y; Hosaka T; Kobayashi M; Arase Y; Ikeda K; Mineta R; Iwasaki S; Watahiki S; Miyakawa Y; Kumada H
Scand J Gastroenterol; 2009; 44(8):975-83. PubMed ID: 19521923
[TBL] [Abstract][Full Text] [Related]
14. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
15. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
16. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
17. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
18. Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis.
Tarao K; Rino Y; Ohkawa S; Tamai S; Miyakawa K; Takakura H; Endo O; Yoshitsugu M; Watanabe N; Matsuzaki S
Cancer; 2002 Mar; 94(6):1787-95. PubMed ID: 11920542
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.
Veldt BJ; Hansen BE; Ikeda K; Verhey E; Suzuki H; Schalm SW
Scand J Gastroenterol; 2006 Sep; 41(9):1087-94. PubMed ID: 16938723
[TBL] [Abstract][Full Text] [Related]
20. [The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis].
Kim MJ; Kwon OS; Chung NS; Lee SY; Jung HS; Park DK; Ku YS; Kim YK; Kim YS; Kim JH
Korean J Hepatol; 2008 Mar; 14(1):67-76. PubMed ID: 18367859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
